Liss H P, Bernstein J
Department of Medicine, Wright State University School of Medicine, Dayton, OH.
Chest. 1988 Jun;93(6):1239-41. doi: 10.1378/chest.93.6.1239.
Ribavirin aerosol is effective in treating respiratory syncytial virus and influenzal infections in children and young adults. It has not been studied in elderly patients. We evaluated the safety of ribavirin aerosol in eight elderly volunteers at high risk for influenza. Their mean age was 64 years; seven subjects had chronic obstructive pulmonary disease (COPD). Subjects received ribavirin aerosol for two or six hours with six hours between treatments. Regimens were continued for 96 hours. The drug was well tolerated. Subjects receiving ribavirin for 2 hours demonstrated a significant decrease in their forced expiratory volume in one second, peak expiratory flow rate and flow over the middle 50 percent of the forced vital capacity. These changes were small and the subjects' symptoms remained stable. Subjects receiving ribavirin for 6 hours had no significant changes in pulmonary function. We conclude that ribavirin aerosol is safe in elderly patients with underlying COPD.
利巴韦林气雾剂对治疗儿童和青年的呼吸道合胞病毒及流感感染有效。尚未在老年患者中进行研究。我们评估了利巴韦林气雾剂在八名有流感高风险的老年志愿者中的安全性。他们的平均年龄为64岁；七名受试者患有慢性阻塞性肺疾病（COPD）。受试者接受利巴韦林气雾剂治疗两小时或六小时，两次治疗间隔六小时。治疗方案持续96小时。该药物耐受性良好。接受利巴韦林治疗两小时的受试者在一秒用力呼气量、呼气峰值流速和用力肺活量中间50%的流速方面有显著下降。这些变化很小，受试者的症状保持稳定。接受利巴韦林治疗六小时的受试者肺功能无显著变化。我们得出结论，利巴韦林气雾剂对患有潜在COPD的老年患者是安全的。
